热门资讯> 正文
Korro宣布进行7000万美元私募
2024-04-18 20:32
- Financing led by Deep Track Capital with participation from other leading healthcare investors
- Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses
- On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024
- Proceeds fund interim readout in the second half of 2025 and FIH study completion in 2026 for KRRO-110
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。